218 related articles for article (PubMed ID: 26438493)
21. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Permar S; Sun Z
J Med Microbiol; 2002 Jan; 51(1):42-49. PubMed ID: 11800471
[TBL] [Abstract][Full Text] [Related]
22. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
Baughn AD; Deng J; Vilchèze C; Riestra A; Welch JT; Jacobs WR; Zimhony O
Antimicrob Agents Chemother; 2010 Dec; 54(12):5323-8. PubMed ID: 20876380
[TBL] [Abstract][Full Text] [Related]
23. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
Njire M; Wang N; Wang B; Tan Y; Cai X; Liu Y; Mugweru J; Guo J; Hameed HMA; Tan S; Liu J; Yew WW; Nuermberger E; Lamichhane G; Liu J; Zhang T
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438933
[TBL] [Abstract][Full Text] [Related]
24. Differentiation among members of the Mycobacterium tuberculosis complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of M. bovis.
Niemann S; Richter E; Rüsch-Gerdes S
J Clin Microbiol; 2000 Jan; 38(1):152-7. PubMed ID: 10618079
[TBL] [Abstract][Full Text] [Related]
25. Identification of Novel Mutations in LprG (
Shi W; Chen J; Zhang S; Zhang W; Zhang Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686155
[TBL] [Abstract][Full Text] [Related]
26. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system.
Suzuki Y; Suzuki A; Tamaru A; Katsukawa C; Oda H
J Clin Microbiol; 2002 Feb; 40(2):501-7. PubMed ID: 11825963
[TBL] [Abstract][Full Text] [Related]
27. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
28. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.
Cheng SJ; Thibert L; Sanchez T; Heifets L; Zhang Y
Antimicrob Agents Chemother; 2000 Mar; 44(3):528-32. PubMed ID: 10681313
[TBL] [Abstract][Full Text] [Related]
29. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?
Heifets LB; Flory MA; Lindholm-Levy PJ
Antimicrob Agents Chemother; 1989 Aug; 33(8):1252-4. PubMed ID: 2508544
[TBL] [Abstract][Full Text] [Related]
30. Estimation of pyrazinamidase activity using a cell-free
Rueda D; Bernard C; Gandy L; Capton E; Boudjelloul R; Brossier F; Veziris N; Zimic M; Sougakoff W
Int J Mycobacteriol; 2018; 7(1):16-25. PubMed ID: 29516881
[TBL] [Abstract][Full Text] [Related]
31. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
Jonmalung J; Prammananan T; Leechawengwongs M; Chaiprasert A
BMC Microbiol; 2010 Aug; 10():223. PubMed ID: 20727143
[TBL] [Abstract][Full Text] [Related]
32. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.
Dillon NA; Peterson ND; Rosen BC; Baughn AD
Antimicrob Agents Chemother; 2014 Dec; 58(12):7258-63. PubMed ID: 25246400
[TBL] [Abstract][Full Text] [Related]
33. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.
Salfinger M; Crowle AJ; Reller LB
J Infect Dis; 1990 Jul; 162(1):201-7. PubMed ID: 2113074
[TBL] [Abstract][Full Text] [Related]
34. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
35. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.
Shi W; Zhang X; Jiang X; Yuan H; Lee JS; Barry CE; Wang H; Zhang W; Zhang Y
Science; 2011 Sep; 333(6049):1630-2. PubMed ID: 21835980
[TBL] [Abstract][Full Text] [Related]
36. Non-
Werngren J; Alm E; Mansjö M
J Clin Microbiol; 2017 Jun; 55(6):1920-1927. PubMed ID: 28404681
[TBL] [Abstract][Full Text] [Related]
37. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
Scorpio A; Lindholm-Levy P; Heifets L; Gilman R; Siddiqi S; Cynamon M; Zhang Y
Antimicrob Agents Chemother; 1997 Mar; 41(3):540-3. PubMed ID: 9055989
[TBL] [Abstract][Full Text] [Related]
38. Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis.
Peterson ND; Rosen BC; Dillon NA; Baughn AD
Antimicrob Agents Chemother; 2015 Dec; 59(12):7320-6. PubMed ID: 26369957
[TBL] [Abstract][Full Text] [Related]
39. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
40. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.
Bhuju S; Fonseca Lde S; Marsico AG; de Oliveira Vieira GB; Sobral LF; Stehr M; Singh M; Saad MH
Infect Genet Evol; 2013 Oct; 19():1-6. PubMed ID: 23770140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
